

# Fibrodynamics-elucidation of the mechanisms and sites of liver fibrogenesis

Catherine H. Wu, Ph.D.

See article on page 397

**Subject headings** liver cirrhosis/pathology; liver cirrhosis/etiology; liver cirrhosis/physiopathology; fibrodynamics; hepatic stellate cells

## ORIGINAL ARTICLE

Dynamic changes of type I, III and IV collagen synthesis and distribution of collagen-producing cells in carbon tetrachloride- induced rat liver fibrosis.

## MAJOR POINTS OF THE COMMENTED ARTICLE

In their article that appears in this issue, Du and colleagues used a combination of immunohistochemistry and *in situ* hybridization to demonstrate increased levels of collagen types I, III and IV in CCl<sub>4</sub>/choline deficient rat model of hepatic fibrosis. Over the course of 20 weeks of treatment mRNA levels for all three types of collagen were increased, but there was a preferential increase of type III collagen mRNA over the other two types. This is consistent with the results of previous investigators<sup>[1,2]</sup> where increases in protein levels of collagen types I, III and IV were found in CCl<sub>4</sub> induced liver fibrosis. The authors clearly demonstrated that collagen type I, III and IV mRNAs were localized on sinusoidal cells using *in situ* hybridization. This result is also consistent with previous work of Maher and co-workers<sup>[3,4]</sup> who used the same technique to demonstrate the localization of both interstitial and basement collagen mRNAs in hepatic stellate cells in normal rat and human livers. The authors have utilized state-of-the-art technology to examine an important question in liver fibrosis-the cells responsible for overproduction of liver biomatrix components. Their results are consistent with the results of other investigators in the field. However, caution should be taken not to overinterpret results.

Additional controls in which the *in situ* localization of collagen mRNAs in untreated normal liver as compared to that seen in fibrotic liver could have given a clearer picture of changes in the fibrotic liver. Nevertheless, the results add strong confirmation to the temporal course of fibrogenesis, and localization of the products in an important model.

## COMMENTARY

Liver fibrosis is the common result of chronic hepatic injury of diverse origins such as chronic viral infections (HBV, HCV), metabolic/storage diseases (hemochromatosis), helminthic infections (schistosomiasis), chronic toxin exposure (alcohol and environmental poisons) and biliary obstruction (biliary cirrhosis). In end stage liver fibrosis or cirrhosis, the liver biomatrix may contain up to six to ten times more collagen and proteoglycans than in the normal state<sup>[5,6]</sup>. Because the connective tissue support of the liver parenchyma is particularly critical to its function, research that emphasizes the nature of liver biomatrix, the molecular regulation of the turnover of components of the biomatrix, and identification of liver cells responsible for the synthesis of biomatrix proteins are especially crucial for the ultimate design of effective therapies for liver fibrosis.

In the late 50's, Hans Popper, the eminent hepatologist, observed a correlation between the histomorphology and biochemistry of liver collagens in chronic liver diseases<sup>[7]</sup>. In the four decades following Dr. Popper's original observation, a great deal of research on liver biomatrix has resulted in our current knowledge of the pathogenesis of liver fibrosis. Progress has been made in three areas of liver fibrosis: characterization and quantitation of matrix components in normal and fibrotic liver; identification of hepatic cells responsible for the increased synthesis of matrix proteins; and the role of cellular mediators of fibrogenesis.

## Quantitation of matrix proteins in normal and fibrotic livers

The use of animal models of liver fibrosis such as the administration of liver toxins CCl<sub>4</sub><sup>[8]</sup>, dimethylnitrosamine<sup>[9]</sup>, alcohol<sup>[10]</sup>, helminthic

Department of Medicine, Division of Gastroenterology-Hepatology, University of Connecticut Health Center, Farmington, CT, USA

**Correspondence to:** Catherine H. Wu, Department of Medicine, Division of Gastroenterology-Hepatology, University of Connecticut Health Center, 263 Farmington Avenue, Farmington, Connecticut 06030, USA

Fax: (860) 679-3159

**Received** 1999-07-01

infections<sup>[11,12]</sup> have greatly helped in the characterization of the temporal expression of various components of the biomatrix during fibrogenesis. There is increase in the amounts of collagens types I, III, IV, V and VI<sup>[1]</sup>. In early fibrosis, the amounts of types III and IV collagens increase relative to other collagens. In late fibrosis, type I collagen predominates<sup>[13]</sup>. Other components of liver biomatrix such as laminin, fibronectin and proteoglycans are also increased in fibrosis<sup>[14,15]</sup>. Although most investigations have shown changes at the protein and mRNA levels of various biomatrix components, the significance of the changes in the fibrogenic process remain hotly debated<sup>[16]</sup>. The biomatrix in the normal liver changes from being rich in basement membrane collagens to interstitial collagens during fibrogenesis.

#### ***Hepatic stellate cells is the major effector cell type in hepatic fibrosis***

The search for effector cells in the liver responsible for collagen synthesis became feasible with the development of molecular probes<sup>[17]</sup> and antibodies<sup>[14,18]</sup> to components of liver biomatrix. Stellate cells are responsible for the increased synthesis in liver biomatrix proteins such as basement membrane collagens, interstitial collagens, fibronectin, laminin and proteoglycans<sup>[3,4]</sup>. Activation of hepatic stellate cells is the earliest response to liver injury. Upon activation, stellate cells lose stored lipids and retinoids<sup>[19]</sup> and rapidly undergo morphological changes to myofibroblast-like phenotype<sup>[20]</sup>. Other phenotypic changes of activated stellate cells include stimulation of  $\alpha$ -actin gene expression<sup>[21,22]</sup> and increased synthesis of hepatic biomatrix components<sup>[3]</sup>. Activation also results in loss of an important feedback regulation of collagen synthesis by its terminal propeptides. In the normal liver, stellate cells are capable of controlling the amount of collagen needed for normal biomatrix formation by a feedback inhibition of collagen synthesis by its terminal propeptides<sup>[23,24]</sup>. Following activation, stellate cells lose their normal feedback regulation of collagen synthesis leading to increased accumulation of collagen<sup>[25]</sup>. In particular, there is an increased synthesis of types I and III collagen resulting in a biomatrix rich in interstitial collagens. There is increasing evidence that accumulation of fibers in the sinusoids is not only due to increased synthesis of collagens, but also is a result of decreased synthesis of tissue collagenases and increased synthesis of inhibitors of collagenase (TIMP-1: tissue inhibitors of metalloprotein-

ase)<sup>[26]</sup>. Thus fibrogenesis is a net result of increased synthesis and decreased degradation of interstitial collagens of activated stellate cells.

#### ***Cellular mediators of hepatic fibrosis***

Understanding the underlying molecular mechanisms responsible for hepatic fibrosis became feasible with the availability of molecular probes to cytokines. It is now accepted that the initial liver injury results in a host of cytokine responses from liver cells. Specifically, TGF $\beta$ <sup>[27]</sup>, TNF $\alpha$ <sup>[28]</sup>, PDGF<sup>[29]</sup> and Kupffer cell soluble factors<sup>[30]</sup> have been implicated in stellate cell activation and proliferation. TGF $\beta$  mRNA and protein levels are increased in activated stellate cells<sup>[27]</sup>. Over-expression of TGF $\beta$  gene in cultured fibroblasts<sup>[27]</sup> and in stellate cells<sup>[31]</sup> results in increased synthesis of collagens. Inhibitors of TGF $\beta$  decrease collagen synthesis *in vivo*<sup>[32,33]</sup> while transgenic mice over expressing TGF $\beta$  have kidney and liver fibrosis<sup>[34]</sup>. Both PDGF<sup>[29]</sup> and TNF $\alpha$ <sup>[35]</sup> are stellate cell mitogens. PDGF-induced stellate cell proliferation and matrix protein synthesis is mediated by factors secreted by Kupffer cells<sup>[30]</sup>. TNF $\alpha$  acts via transcription regulation of tissue collagenase and TIMP-1 genes in activated stellate cells<sup>[28]</sup>.

#### ***Current research***

The elucidation of the molecular mechanisms of cytokine regulation of liver biomatrix protein synthesis continue to be a focus of current research efforts. There is increasing evidence that cytokines may act via interactions with DNA binding proteins to affect matrix proteins synthesis. Both TGF $\beta$  and TNF $\alpha$  interact with known transcription factors such as C/EBP<sup>[36]</sup> and NF $\kappa$ B<sup>[37,38]</sup>. Transcription factors are DNA binding proteins which act as regulators of gene transcriptions<sup>[39,40]</sup>. There is continued interest in the search for regulatory elements within genes of matrix proteins<sup>[41]</sup>. Research on interactions of DNA binding proteins to regulatory elements on matrix protein genes are underway and may provide a link between cytokines and regulation of liver biomatrix.

#### ***Future directions***

Effective therapy for chronic hepatic fibrosis can be designed only with complete understanding of the molecular mechanisms that regulate matrix protein gene expression. Future research may be centered on the application of gene therapy to control hepatic fibrosis<sup>[42]</sup>. Over-expression of tissue collagenase gene, inhibition of TGF $\beta$  gene expression are potential approach in controlling and regulating hepatic fibrosis<sup>[43]</sup>.

## REFERENCES

- 1 Schuppan D. Structure of the extracellular matrix in normal and fibrotic livers: collagens and glycoproteins. *Sem Liver Dis*, 1990; 10:1-10
- 2 Greenwel P, Rojkind M. Accelerated development of liver fibrosis in CCl<sub>4</sub> treated rats by the introduction of acute phase response episodes: upregulation of alpha (I) procollagen and tissue inhibitor of metalloproteinase-1 mRNAs. *Biochim et Biophys Acta*, 1997;1361:177-184
- 3 Maher JJ, McGurie RF. Extracellular matrix gene expression increases preferentially in rat lipocytes and sinusoidal endothelial cells during hepatic fibrosis *in vivo*. *J Clin Invest*, 1980;86:1641-1648
- 4 Friedman SL, Roll FJ, Boyles J, Bissell DM. Hepatic lipocytes: the principal collagen producing cells of normal rat liver. *Proc Natl Acad Sci USA*, 1985;82:8681-8685
- 5 Rojkind M, Kershenovich D. Hepatic fibrosis. *Progress in Liver Diseases*, 1976;5:294-310
- 6 Schuppan D. Structure of the extracellular matrix in normal and fibrotic livers: collagens and glycoproteins. *Sem Liver Dis*, 1990; 10:1-10
- 7 Kent G, Fels IG, Dubin A, Popper H. Collagen content based on hydroxyproline determinations in human and rat livers: its relation to morphologically demonstrable reticulum and collagen fibers. *Lab Invest*, 1959;8:48
- 8 Rojkind M, Giambrone MA, Ehrenpreise M. Proline oxidase activity and the availability of proline for collagen biosynthesis in Livers of CCl<sub>4</sub> treated rats. *Gastroenterology*, 1977;73:1243
- 9 Risteli J, Tuderman L, Kivirikko KI. Intracellular enzymes of collagen biosynthesis in rat liver as a function of age and in hepatic injury produced by dimethylnitrosamine. *Biochem J*, 1976;158:369-376
- 10 Mezey E, Potter JJ, Maddrey WC. Hepatic collagen proline hydroxylase activity in alcoholic liver disease. *Clin Chem Acta*, 1976; 68:313-320
- 11 Dunn MA, Rojkind M, Warren KS, Hait PK, Rifas L, Seifter S. Gene therapy by skeletal muscle expression of decorin prevents fibrotic disease in rat kidney. *Nature Med*, 1996;2:418-423
- 12 Wu CH, Giambrone MA, Howard DJ, Rojkind M, Wu GY. The nature of collagen of hepatic fibrosis in advanced murine schistosomiasis. *Hepatology*, 1982;2:366-371
- 13 Rojkind M, Giambrone MA, Biempica L. Collagen types in normal and cirrhotic liver. *Gastroenterology*, 1979;76:710-719
- 14 Geerts A, Geutz HJ, Slot JW. Immunogold localization of procollagen III, fibronectin and heparan sulfate proteoglycan on ultrathin frozen sections of the normal rat liver. *Histochemistry*, 1986;84:355-362
- 15 Reid LM, Fiorino AS, Sigal SH, Brill, Holst PA. Extracellular matrix gradients in the space of Disse: relevance to liver biology. *Hepatology*, 1992;15:1198-1203
- 16 Jarnagin WR, Rochey DC, Kotliansky VE, Wang SS, Bissell DM. Expression of variant fibronectins in wound healing: cellular sources and biological activity of EIIIA segment in rat fibrogenesis. *J Cell Biol*, 1994;127:2037-2048
- 17 Adams SI. Regulation of collagen gene expression. in *Extracellular Matrix: Chemistry, Biology, and Pathobiology with emphasis on the liver*. Zern MA and Reid LM (eds). Marcel Dekker, Inc. New York, 1993:p91-119
- 18 Becker J, Schuppan D, Benzan H. Immunohistochemical distribution of collagen types IV, V, VI and procollagen types I and III in human alveolar bone and dentine. *J Histochem Cytochem*, 1987; 34:1417-1429
- 19 Mak KM, Leo AM, Lieber CS. Alcoholic liver injury in baboons: transformation of lipocytes to transitional cells. *Gastroenterology*, 1984;87:188-200
- 20 Mak KM, Leo AM, Lieber CS. Alcoholic liver injury in baboons: transformation of lipocytes to transitional cells. *Gastroenterology*, 1984;87:188-200
- 21 Tanaka Y, Nouchi T, Yamane M, Irie T, Miyakawa H, Sato C, Marumo F. Phenotypic modulation in lipocytes in experimental liver fibrosis. *J Pathol*, 1991;164:273-278
- 22 Rockey DC, Boyles JK, Gabbiani G, Friedman SL. Rat hepatic lipocytes express smooth muscle actin upon activation *in vivo* and in culture. *J Submicrosc Cytol Pathol*, 1992;24:193-203
- 23 Wu CH, Donovan CB, Wu GY. Evidence for pre translational regulation of collagen synthesis by procollagen propeptides. *J Biol Chem*, 1986;261:10482-10484
- 24 Wu CH, Walton CM, Wu GY. Propeptide-mediated regulation of procollagen synthesis in IMR-90 human lung fibroblast cell cultures. *J Biol Chem*, 1991;266:2983-2987
- 25 Ikeda H, Wu GY, Wu CH. Lipocytes from fibrotic rat liver have an impaired feedback response to procollagen propeptides. *Am J Physiol*, 1993;27:G157-162
- 26 Iredale JP, Murhy G, Hembry RM, Friedman SL, Arther MJP. Human hepatic lipocytes synthesize tissue inhibitor of metalloproteinases-1 (TIMP-1): implications for regulation of matrix degradation in liver. *J Clin Invest*, 1992;90:282-287
- 27 Roberts AB, Sporn MB, Assoian RK, Smith JM, Roche NS, Wakefield LM, Heine UI, Liotta LA, Falanga V, Kehrl JH, Fauci AS. Transforming growth factor type $\beta$ : Rapid induction of fibrosis and angiogenesis *in vivo* and stimulation of collagen formation *in vitro*. *Proc Natl Acad Sci USA*, 1986;83:4167-4171
- 28 Iredale JP. Matrix turnover in fibrogenesis. *Hepato-Gastroenterology*, 1996;43:56-71
- 29 Pinzani M, Gesukado L, Aabbah GM and Abboud HE. Effects of platelet derived growth factor and other polypeptide mitogens on DNA synthesis and growth of cultured rat liver fat storing cells. *J Clin Invest*, 1989;84:1786-1793
- 30 Friedman SL, Arthur MJP. Activation of cultured rat hepatic lipocytes by Kupffer cell conditioned medium. Direct enhancement of matrix synthesis and stimulation of cell proliferation via induction of platelet derived growth factor receptors. *J Clin Invest*, 1989;84:1780-1785
- 31 Milani S, Schuppan D, Herbst H, Surrenti C. Expression of transforming-growth factor beta, in normal and fibrotic human liver. In: Gressner A, Ramadori G, eds. *Molecular and cell biology of liver fibrogenesis*. Dordrecht, The Netherlands: Kluwer Academic Publishers, 1992:254-263
- 32 Border WA, Noble NA, Yamamoto T. Natural inhibitor of transforming growth factor beta protects against scarring in experimental kidney disease. *Nature (London)*, 1990;360:361-364
- 33 Shah M, Foreman DM, Ferguson MWJ. Control of scarring in adult wounds by neutralizing antibody to transforming growth factor beta. *Lancet*, 1992;339:213-214
- 34 Sanderson N, Factor V, Nagy P. Hepatic expression of mature transforming growth factor beta 1 in transgenic mice results in multiple tissue lesions. *Proc Natl Acad Sci USA*, 1995;92:2572-2576
- 35 Camussi G, Albano E, Tetta C and Bussolino F. The molecular action of tumor necrosis factor- $\alpha$ . *Eur J Biochem*, 1991;202:3-14
- 36 Garcia-Trevijano ER, Iraburu MJ, Fontana L, Dominguez-Rosales JA, Auster A, Covarrubias-Pinedo A, Rojkind M. Transforming growth factor beta<sub>1</sub> induces the expression of alpha (I) procollagen mRNA by a hydrogen peroxide-C/EBPbeta-dependent mechanism in rat hepatic stellate cells. *Hepatology*, 1999;29:960-970
- 37 Zeldin G, Yang SQ, Yin M, Lin HZ, Rai R, Diehl AM. Alcohol and cytokine-inducible transcription factors. *Alcoholism, Clinical & Experimental Research*, 1996;20:1639-1645
- 38 Yang SQ, Lin HZ, Yin M, Albrecht JH, Diehl AM. Effects of chronic ethanol consumption on cytokine regulation of liver regeneration. *Am J Physiol*, 1998;275:G696-704
- 39 Hellerbrand C, Stefanovic B, Giordano F, Burchardt ER, Brenner DA. The role of TGFbeta 1 in initiating hepatic stellate cell activation *in vivo*. *J Hepatology*, 1999;30:77-87
- 40 Hellerbrand C, Jobin C, Licato LL, Sartor RB, Brenner DA. Cytokines induce NF-kappa B in activated but not in quiescent rat hepatic stellate cells. *Am J Physiol*, 1998;275:G269-278
- 41 Stefanovic B, Hellerbrand C, Holcik M, Briendl M, Aliehaber S and Brenner DA. Post transcriptional regulation of collagen alpha 1(I) mRNA in hepatic stellate cells. *Mol Cell Biol*, 1997;17:5201-5209
- 42 Hellerbrand C, Jobin C, Iimuro Y, Licato L, Sartor RB, Brenner DA. Inhibition of NFkappaB in activated rat hepatic stellate cells by proteasome inhibitors and an IkappaB super repressor. *Hepatology*, 1998;27:1285-1295
- 43 Isaka Y, Brees DK, Ikegaya K, Kaneda Y, Imai E, Noble NA, Border WA. Gene therapy by skeletal muscle expression of decorin prevents fibrotic disease in rat kidney. *Nature Med*, 1996;2:418-423